IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
36.20
+0.19 (0.53%)
Jan 22, 2026, 4:00 PM EST - Market closed
IDEAYA Biosciences Revenue
IDEAYA Biosciences had revenue of $207.83M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $214.83M, up 5,377.66% year-over-year. In the year 2024, IDEAYA Biosciences had annual revenue of $7.00M, down -70.07%.
Revenue (ttm)
$214.83M
Revenue Growth
+5,377.66%
P/S Ratio
14.86
Revenue / Employee
$1,639,954
Employees
131
Market Cap
3.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.00M | -16.39M | -70.07% |
| Dec 31, 2023 | 23.39M | -27.55M | -54.08% |
| Dec 31, 2022 | 50.93M | 22.99M | 82.28% |
| Dec 31, 2021 | 27.94M | 8.40M | 43.01% |
| Dec 31, 2020 | 19.54M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Catalyst Pharmaceuticals | 578.20M |
| Tarsus Pharmaceuticals | 366.10M |
| Arcutis Biotherapeutics | 317.93M |
| Viridian Therapeutics | 70.79M |
| Liquidia | 69.22M |
| Beam Therapeutics | 55.70M |
| Centessa Pharmaceuticals | 15.00M |
| Xenon Pharmaceuticals | 7.50M |
IDYA News
- 10 days ago - IDEAYA Biosciences, Inc. (IDYA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 11 days ago - IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 18 days ago - IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 6 weeks ago - IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma - PRNewsWire
- 6 weeks ago - IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers - PRNewsWire
- 7 weeks ago - IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance - Business Wire
- 7 weeks ago - IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 7 weeks ago - IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types - PRNewsWire